A Phase 1 interventional study of Moxifloxacin and DAV132 in Healthy Subjects, sponsored by Da Volterra. Completed at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-12.
Sponsored by Da Volterra · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate whether different DAV132 dose regimens are safe and effective for capturing fecal residues of moxifloxacin in healthy volunteers.
The aim of the study is to evaluate the performances of different DAV132 dose regimens in healthy volunteers:
This is a prospective, randomized, controlled, repeated doses, 12 parallel groups, open-label study, blinded to analytical and microbiological evaluations.
Da Volterra is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females participating in the study:
Exclusion Criteria:
Criteria related to the healthy status
Presence or history of drug , or allergic disease diagnosed and treated by a physician.
Criteria specific to the study
Any previous administration of medication and any previous intake of herbal products known to interfere with drug metabolism such as St John's Wort within the last 14 days, with the exception of hormonal or menopausal hormone replacement therapy or paracetamol.
Criteria associated with addiction
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Moxifloxacin, 400 mg/day oad, 5 days + Negative control, tid, 7 days
Drug: Moxifloxacin · Other: Negative control
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g tid, 7 days
Drug: Moxifloxacin · Device: DAV132
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g bid, 7 days
Drug: Moxifloxacin · Device: DAV132
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g tid, 7 days
Drug: Moxifloxacin · Device: DAV132
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g bid, 7 days
Drug: Moxifloxacin · Device: DAV132
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3.3 g tid, 7 days
Drug: Moxifloxacin · Device: DAV132
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3 g bid, 7 days
Drug: Moxifloxacin · Device: DAV132
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 2 g tid, 7 days
Drug: Moxifloxacin · Device: DAV132
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1.5 g bid, 7 days
Drug: Moxifloxacin · Device: DAV132
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g tid, 7 days
Drug: Moxifloxacin · Device: DAV132
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g bid, 7 days
Drug: Moxifloxacin · Device: DAV132
Negative control, tid, 7 days
Other: Negative control
Oral route
Oral route
Oral route
Area under the curve of free moxifloxacin fecal concentrations from D1 to D16 (AUC D1-D16)
Time frame: over 16 days after treatment start
Bacterial diversity of the intestinal microbiota (16S rDNA profiling)
Time frame: over 37 days after treatment start
Area under the curve of moxifloxacin plasma concentrations from 0 to 24 hours (AUC0-24h) on D1 and D5
Time frame: over 5 days after treatment start
Maximum moxifloxacin plasma concentrations (Cmax) on D1 and D5
Time frame: over 5 days after treatment start
Number of adverse events and percentage of subjects with at least one adverse event
Time frame: over 37 days after treatment start
Number of subjects with samples positive for treatment-emergent quinolone / fluoroquinolone-resistant Enterobacteriaceae
Time frame: over 37 days after treatment start
Occurrence of Clostridium difficile infection, evaluated by identification of C. difficile in diarrheic stools
Time frame: over 37 days after treatment start
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2016 to primary completion in Dec 2016, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin
Da Volterra